Key clinical point: Karnofsky Performance Status (KPS) is predictive of 5-year survival in patients with autoimmune-related liver disease who undergo a transplant.
Major finding: After 5 years, 84.9% of autoimmune hepatitis patients with a KPS of 1 were alive, compared with 76.1% of those with a KPS of 4 (P less than .01).
Study details: A retrospective study involving 6,628 patients with autoimmune-related liver disease who underwent liver transplant.
Disclosures: The investigators disclosed relationships with Gilead, Salix, and AbbVie.
Galoosian A et al. The Liver Meeting 2019. Abstract 1102.